Benitec Biopharma Statistics
Total Valuation
BNTC has a market cap or net worth of $386.15 million. The enterprise value is $206.94 million.
| Market Cap | 386.15M |
| Enterprise Value | 206.94M |
Important Dates
The last earnings date was Monday, September 14, 2026, after market close.
| Earnings Date | Sep 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BNTC has 34.88 million shares outstanding. The number of shares has increased by 28.58% in one year.
| Current Share Class | 34.88M |
| Shares Outstanding | 34.88M |
| Shares Change (YoY) | +28.58% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 2.61% |
| Owned by Institutions (%) | 54.12% |
| Float | 18.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.15 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 34.00, with a Debt / Equity ratio of 0.00.
| Current Ratio | 34.00 |
| Quick Ratio | 33.68 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.21% and return on invested capital (ROIC) is -23.19%.
| Return on Equity (ROE) | -33.21% |
| Return on Assets (ROA) | -22.67% |
| Return on Invested Capital (ROIC) | -23.19% |
| Return on Capital Employed (ROCE) | -28.88% |
| Weighted Average Cost of Capital (WACC) | 5.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.40M |
| Employee Count | 19 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.20% in the last 52 weeks. The beta is 0.27, so BNTC's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -19.20% |
| 50-Day Moving Average | 12.54 |
| 200-Day Moving Average | 12.06 |
| Relative Strength Index (RSI) | 33.44 |
| Average Volume (20 Days) | 133,768 |
Short Selling Information
The latest short interest is 2.21 million, so 6.35% of the outstanding shares have been sold short.
| Short Interest | 2.21M |
| Short Previous Month | 2.11M |
| Short % of Shares Out | 6.35% |
| Short % of Float | 12.00% |
| Short Ratio (days to cover) | 12.29 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -51.19M |
| Pretax Income | -45.55M |
| Net Income | -45.55M |
| EBITDA | -51.13M |
| EBIT | -51.19M |
| Earnings Per Share (EPS) | -$0.98 |
Balance Sheet
The company has $179.97 million in cash and $762,000 in debt, with a net cash position of $179.21 million or $5.14 per share.
| Cash & Cash Equivalents | 179.97M |
| Total Debt | 762,000 |
| Net Cash | 179.21M |
| Net Cash Per Share | $5.14 |
| Equity (Book Value) | 177.01M |
| Book Value Per Share | 5.14 |
| Working Capital | 176.34M |
Cash Flow
In the last 12 months, operating cash flow was -$16.52 million and capital expenditures -$105,000, giving a free cash flow of -$16.62 million.
| Operating Cash Flow | -16.52M |
| Capital Expenditures | -105,000 |
| Depreciation & Amortization | 58,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -16.62M |
| FCF Per Share | -$0.48 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BNTC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.58% |
| Shareholder Yield | -28.58% |
| Earnings Yield | -11.83% |
| FCF Yield | -4.32% |
Analyst Forecast
The average price target for BNTC is $24.33, which is 119.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.33 |
| Price Target Difference | 119.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 26, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | Jul 26, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |